Antony C. Mattessich net worth and biography

Antony Mattessich Biography and Net Worth

CEO of Ocular Therapeutix

Antony Mattessich joined Ocular as Chief Executive Officer in August of 2017. Prior to joining the company, he was Managing Director of Mundipharma International based in Cambridge, England. Previous to his time at Mundipharma, Antony ran the US respiratory, dermatology and pediatrics group at Novartis. He also held several positions at Bristol-Myers Squibb, among them, Managing Director roles in Malaysia/Singapore and The Netherlands, and Head of Operations for the International Medicines Group. Antony holds a BA from the University of California at Berkeley and a Masters in International Affairs from Columbia University.

What is Antony C. Mattessich's net worth?: The estimated net worth of Antony C. Mattessich is at least $3.24 million as of January 31st, 2024. Mr. Mattessich owns 427,943 shares of Ocular Therapeutix stock worth more than $3,239,529 as of April 14th. This net worth estimate does not reflect any other investments that Mr. Mattessich may own. Learn More about Antony C. Mattessich's net worth.
How do I contact Antony C. Mattessich?: The corporate mailing address for Mr. Mattessich and other Ocular Therapeutix executives is 15 CROSBY DRIVE, BEDFORD MA, 01730. Ocular Therapeutix can also be reached via phone at (781) 357-4000 and via email at chris.brinzey@westwicke.com. Learn More on Antony C. Mattessich's contact information.
Has Antony C. Mattessich been buying or selling shares of Ocular Therapeutix?: Antony C. Mattessich has not been actively trading shares of Ocular Therapeutix in the last ninety days. Most recently, Antony C. Mattessich sold 18,338 shares of the business's stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $4.95, for a transaction totalling $90,773.10. Following the completion of the sale, the chief executive officer now directly owns 427,943 shares of the company's stock, valued at $2,118,317.85. Learn More on Antony C. Mattessich's trading history.
Who are Ocular Therapeutix's active insiders?: Ocular Therapeutix's insider roster includes Pravin Dugel (Executive Chairman, President and CEO), Jeffrey Heier (Chief Scientific Officer), Richard Lindstrom (Director), Antony Mattessich (CEO), Sanjay Nayak (Insider), and Donald Notman (Chief Financial Officer and Chief Operating Officer). Learn More on Ocular Therapeutix's active insiders.
Are insiders buying or selling shares of Ocular Therapeutix?: During the last year, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 45,949 shares worth more than $340,138.76. The most recent insider tranaction occured on February, 24th when insider Pravin Dugel sold 21,475 shares worth more than $147,533.25. Insiders at Ocular Therapeutix own 3.5% of the company. Learn More about insider trades at Ocular Therapeutix.
Information on this page was last updated on 2/24/2025.

Antony C. Mattessich Insider Trading History at Ocular Therapeutix

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/31/2024	Sell	18,338	$4.95	$90,773.10	427,943
8/30/2023	Buy	6,500	$3.81	$24,765.00	6,500
2/6/2023	Sell	19,669	$4.24	$83,396.56	446,281
8/20/2021	Buy	5,000	$9.89	$49,450.00	102,900
6/6/2019	Buy	40,000	$2.81	$112,400.00	97,900
8/20/2018	Buy	20,000	$5.95	$119,000.00	57,900
8/10/2018	Buy	16,900	$6.23	$105,287.00	37,900
12/12/2017	Buy	21,000	$4.29	$90,090.00	21,000

Antony C. Mattessich Buying and Selling Activity at Ocular Therapeutix

Ocular Therapeutix Company Overview

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Today's Range

Now: $7.57

$7.03

$7.64

50 Day Range

MA: $7.24

$5.93

$8.51

2 Week Range

Now: $7.57

$4.06

$11.78

Volume

1,455,486 shs

Average Volume

1,569,582 shs

Market Capitalization

$1.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49